142 related articles for article (PubMed ID: 25957329)
1. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sunakawa Y; Sebio A; Yamauchi S; Matsusaka S; Parekh A; Barzi A; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Ann Oncol; 2015 Aug; 26(8):1728-33. PubMed ID: 25957329
[TBL] [Abstract][Full Text] [Related]
2. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
Stremitzer S; Sunakawa Y; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Pharmacogenomics J; 2015 Dec; 15(6):521-9. PubMed ID: 25752522
[TBL] [Abstract][Full Text] [Related]
3. Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.
Stremitzer S; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Sunakawa Y; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Cancer; 2015 Jun; 121(11):1898-905. PubMed ID: 25690670
[TBL] [Abstract][Full Text] [Related]
4. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
6. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
7. NME1 and DCC variants are associated with susceptibility and tumor characteristics in Mexican patients with colorectal cancer.
Márquez-González RM; Saucedo-Sariñana AM; de Jesús Tovar-Jacome C; Barros-Núñez P; Gallegos-Arreola MP; Orozco-Gutiérrez MH; Mariscal-Ramírez I; Pineda-Razo TD; Alcaraz-Wong AA; Marín-Contreras ME; Rosales-Reynoso MA
J Egypt Natl Canc Inst; 2024 Apr; 36(1):10. PubMed ID: 38556604
[TBL] [Abstract][Full Text] [Related]
8. Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases.
Nishioka Y; Shindoh J; Inagaki Y; Gonoi W; Mitsui J; Abe H; Yoshioka R; Yoshida S; Fukayama M; Tsuji S; Hashimoto M; Hasegawa K; Kokudo N
Dig Dis; 2018; 36(6):437-445. PubMed ID: 29969766
[TBL] [Abstract][Full Text] [Related]
9. Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases.
Stift J; Graf A; Schwarz C; Tamandl D; Starlinger P; Herac M; Beer A; Wrba F; Bodingbauer M; Kaczirek K; Stremitzer S
Eur J Surg Oncol; 2018 Jan; 44(1):139-147. PubMed ID: 29203074
[TBL] [Abstract][Full Text] [Related]
10. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
[TBL] [Abstract][Full Text] [Related]
11. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
12. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.
Yamashita S; Odisio BC; Huang SY; Kopetz SE; Ahrar K; Chun YS; Conrad C; Aloia TA; Gupta S; Harmoush S; Hicks ME; Vauthey JN
Eur J Surg Oncol; 2017 Jun; 43(6):1040-1049. PubMed ID: 28187878
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
14. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Notch receptors in postsurgical patients with hepatitis B virus-related hepatocellular carcinoma.
Yu T; Han C; Zhu G; Liao X; Qin W; Yang C; Liu Z; Su H; Liu X; Yu L; Liu Z; Lu S; Chen Z; Liang Y; Huang J; Qin X; Gui Y; Li J; Peng T
Cancer Med; 2017 Jul; 6(7):1587-1600. PubMed ID: 28568708
[TBL] [Abstract][Full Text] [Related]
16. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.
Maker AV; Ito H; Mo Q; Weisenberg E; Qin LX; Turcotte S; Maithel S; Shia J; Blumgart L; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Cancer Immunol Res; 2015 Apr; 3(4):380-8. PubMed ID: 25600439
[TBL] [Abstract][Full Text] [Related]
17. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Adjuvant Chemotherapy after Hepatic Resection for Synchronous and Early Metachronous Colorectal Liver Metastases.
Nishioka Y; Moriyama J; Matoba S; Kuroyanagi H; Hashimoto M; Shindoh J
Dig Surg; 2018; 35(3):187-195. PubMed ID: 28848205
[TBL] [Abstract][Full Text] [Related]
19. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
[TBL] [Abstract][Full Text] [Related]
20. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
